EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
about
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.
@en
EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.
@nl
type
label
EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.
@en
EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.
@nl
prefLabel
EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.
@en
EGFR and KRAS mutations do not ...... resected lung adenocarcinoma.
@nl
P2093
P2860
P1433
P1476
EGFR and KRAS mutations do not ...... n resected lung adenocarcinoma
@en
P2093
Alexander Dobrovic
Benjamin Solomon
Gavin M Wright
Matthew Conron
Melissa M Moore
Prudence A Russell
Sue-Anne McLachlan
Vijaya Sundararajan
P2860
P2888
P356
10.1007/S12032-017-1031-1
P577
2017-09-06T00:00:00Z